Search
fedratinib (Inrebic)
Indications:
- treatment of myeloproliferative diseases including myelofibrosis
Dosage:
- 100 mg oral capsule
Monitor:
- liver function tests
Adverse effects:
- common:
- diarrhea, nausea, vomiting, fatigue, muscle spasm
- iron-deficiency anemia, thrombocytopenia
- hepatotoxicity
- increased serum amylase or serum lipase
- boxed warning risk of serious & fatal encephalopathy, including Wernicke's encephalopathy
Mechanism of action:
- semi-selective inhibitor of Janus kinase 2 (JAK2)
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=16722836
References
- PubChem: 16722836
- Wikipedia: Fedratinib
https://en.wikipedia.org/wiki/Fedratinib
- Pardanani A, Hood J, Lasho T et al
TG101209, a small molecule JAK2-selective kinase inhibitor
potently inhibits myeloproliferative disorder-associated
JAK2V617F and MPLW515L/K mutations.
Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31.
PMID 17541402
- FDA News Release. Aug 16, 2919
FDA approves treatment for patients with rare bone marrow disorder.
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder